Connecticut pauses plan to pursue lower-cost GLP-1s

Connecticut has halted efforts to secure federal approval for a partnership with a generic drug manufacturer to reduce the cost of GLP-1 medications, despite a state mandate to pursue such measures. This move comes amid broader concerns about the high prices of these drugs, which are widely used for diabetes and weight management. The decision underscores the tension between legislative intent and practical execution, highlighting the complexities involved in drug pricing and affordability in the healthcare system.